Last reviewed · How we verify
NCT03712267
Electronic Media and Its Application in Psychotherapy
NA trial testing Electronic Media Enhanced in Anxiety Disorders in 110 participants. Completed in 31 August 2023.
31 August 2023
Quick facts
| Lead sponsor | Mclean Hospital |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | supportive care |
| Enrollment | 110 |
| Start date | 13 December 2018 |
| Primary completion | 31 August 2023 |
| Estimated completion | 31 August 2023 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Electronic Media Enhanced
- Treatment as Usual
Conditions studied
- Anxiety Disorders — all drugs for Anxiety Disorders →
- Depression — all drugs for Depression →
- Electronic Media — all drugs for Electronic Media →
Sponsor
Mclean Hospital
Who can join
Adults 14 to 85, any sex, with Anxiety Disorders or Depression. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This randomized control trial aims to establish whether viewing and discussing patients' electronic communication (texts, emails, Facebook direct messaging, etc) impacts clinical care and decision making across the lifespan.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03712267
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Anxiety Disorders
Currently open trials in the same condition.
- NCT07340281 — Biomarkers for Exercise · NA · recruiting
- NCT07432945 — In Vivo Exposure vs. Videochat-Based Vicarious Exposure · NA · recruiting
- NCT07316374 — AI Chatbots for Anxiety Mental Health Literacy · NA · active not recruiting
- NCT07123467 — Cannabidiol-Assisted Learning for Managing Generalized Anxiety Disorder · Phase 3 · recruiting
- NCT07174947 — SSRI Antidepressant Fluoxetine Improving Immunotherapy Efficacy in Advanced Hepatobiliary Malignancy Patients With Depre · Phase 2 · recruiting
Other Mclean Hospital trials
Trials by the same sponsor.
- NCT07519759 — Recovery Inspired Support Engagement (RISE) Pilot · NA · not yet recruiting
- NCT07503093 — Pilot Study of Sensor-Informed Smartphone-based Mental Health Interventions for Mood in Early Psychosis · NA · not yet recruiting
- NCT07503067 — Identifying Substance Use Consequences · recruiting
- NCT06816329 — Stress Dynamics and Familial Risk for Depression in Female Adolescents · NA · recruiting
- NCT06876129 — Pharmacologic Augmentation of TMS for Depression With D-serine · Phase 1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03712267 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Mclean Hospital
- Last refreshed: 5 November 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03712267.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing